**Supporting Information**

**for**

**In silico approach: Anthocyanin derivatives as potential inhibitors of the COVID-19 main protease**

Muhammad Ikhlas Abdjan1, Khusna Arif Rakhman2, Sri Handayani3, Chairil Anjasmara Robo Putra4, Imam Siswanto1\*

1Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga, kampus C Mulyorejo, Surabaya 60115, Indonesia

2Department of Chemistry Education, Universitas Khairun, Ternate, Indonesia

3Department of Chemical Education, Faculty of Mathematics and Natural Sciences, State University of Yogyakarta, Yogyakarta, Indonesia

4Post Graduate School, Universitas Airlangga, Jl. Dharmawangsa 30, Surabaya 60286, Indonesia

Email: imamsiswanto@fst.unair.ac.id

\* Corresponding author

**Additional data**

**Solvent Accessibility Surface Area**



**Figure S1:** Solvent accessibility surface area of COVID-19 main protease active site plot along the simulation time (200 ns) of each complex: (A) X77, (B) C5, and (C) C6.

**Bioavailability and Drug-Likeness Screening**

**Table S1:** Prediction of ADMET properties used admetSAR service website.

|  |  |  |
| --- | --- | --- |
| Parameters | Code C5 | Code C6 |
| Blood-brain barrier | BBB- | BBB- |
| Human intestinal absorption | HIA+ | HIA+ |
| P-glycoprotein substrate | Substrate | Substrate |
| P-glycoprotein inhibitor | Non-inhibitor | Non-inhibitor |
| Renal organic cation transporter | Non-inhibitor | Non-inhibitor |
| Aqueous solubility (LogS) | -2.63 | -2.10 |
| Subcellular localization | Mitochondria | Mitochondria |
| CYP450 2C9 subtrate | Non-substrate | Non-substrate |
| CYP450 2C9 inhibitor | Non-inhibitor | Non-inhibitor |
| CYP450 2D6 subtrate | Non-substrate | Non-substrate |
| CYP450 2D6 inhibitor | Non-inhibitor | Non-inhibitor |
| CYP450 3A4 subtrate | Non-substrate | Non-substrate |
| CYP450 3A4 inhibitor | Non-inhibitor | Non-inhibitor |
| CYP450 1A2 inhibitor | Non-inhibitor | Non-inhibitor |
| CYP450 2C19 inhibitor | Non-inhibitor | Non-inhibitor |
| Human ether-a-go-go-related-gene-inhibition | Weak inhibitor | Weak inhibitor |
| AMES toxicity | Non-AMES toxic | Non-AMES toxic |
| carcinoges | Non-Carcinogens | Non-Carcinogens |
| biodegradation | Not-ready-biodegradable | Not-ready-Biodegradable |
| Acute oral toxicity | III | IV |
| Carcinogenicity (three-class) | Non-required | Non-required |
| Rat acute toxicity (LD50, mol/kg) | 2.27 | 2.16 |